The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Impact of bendamustine exposure in patients with R/R FL treated with odronextamab in the ELM-2 trial
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses an analysis of data from the Phase II ELM-2 study (NCT03888105), which assessed the impact of prior bendamustine exposure on outcomes of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with the bispecific antibody odronextamab. Prof. Danilov highlights that prior exposure to bendamustine did not significantly impact efficacy, with comparable response rates and progression-free survival between groups. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
